MedTrace Logo

A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan

NCT05882279 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2024-06-14

Study results available
· View outcomes & findings →

Summary

This is a survey among pharmacists who have instructed NINLARO therapy in ixazomib, lenalidomide and dexamethasone (IRD) dosing to patients with relapsed/refractory multiple myeloma (rrMM).

The main aims of the study are:

* To assess the frequency of pharmacists who have provided patients with the contents of the RMP material for patients.
* To assess the frequency of pharmacists who have obtained the RMP material for patients.
* To evaluate the depth of understanding of proper usage of NINLARO among pharmacists.

Conditions

Interventions

OTHER

No Intervention

This is a non-interventional study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2023-06-09
Completion
2023-06-09

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05882279 on ClinicalTrials.gov